Synthetic Peptides as cGMP-Independent Activators of cGMP-Dependent Protein Kinase Iα

被引:8
|
作者
Moon, Thomas M. [1 ]
Tykocki, Nathan R. [1 ]
Sheehe, Jessica L. [1 ]
Osborne, Brent W. [1 ]
Tegge, Werner [2 ]
Brayden, Joseph E. [1 ]
Dostmann, Wolfgang R. [1 ]
机构
[1] Univ Vermont, Coll Med, Dept Pharmacol, Burlington, VT 05405 USA
[2] Helmholtz Ctr Infect Res HZI, Dept Biol Chem, D-38124 Braunschweig, Germany
来源
CHEMISTRY & BIOLOGY | 2015年 / 22卷 / 12期
基金
美国国家卫生研究院;
关键词
CYCLIC-NUCLEOTIDE ANALOGS; SOLUBLE GUANYLATE-CYCLASE; TRACHEAL SMOOTH-MUSCLE; SENSITIVE K+ CHANNEL; NITRIC-OXIDE; CEREBRAL-ARTERIES; SIGNALING PATHWAY; DRUG DEVELOPMENT; RELAXATION; DISCOVERY;
D O I
10.1016/j.chembiol.2015.11.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
PKG is a multifaceted signaling molecule and potential pharmaceutical target due to its role in smooth muscle function. A helix identified in the structure of the regulatory domain of PKG I alpha suggests a novel architecture of the holoenzyme. In this study, a set of synthetic peptides (S-tides), derived from this helix, was found to bind to and activate PKG I alpha in a cyclic guanosine monophosphate (cGMP)-independent manner. The most potent S-tide derivative (S1.5) increased the open probability of the potassium channel K(Ca)1.1 to levels equivalent to saturating cGMP. Introduction of S1.5 to smooth muscle cells in isolated, endothelium-denuded cerebral arteries through a modified reversible permeabilization procedure inhibited myogenic constriction. In contrast, in endothelium-intact vessels S1.5 had no effect on myogenic tone. This suggests that PKG Ia activation by S1.5 in vascular smooth muscle would be sufficient to inhibit augmented arterial contractility that frequently occurs following endothelial damage associated with cardiovascular disease.
引用
收藏
页码:1653 / 1661
页数:9
相关论文
共 50 条
  • [1] Myosin light chain kinase A is activated by cGMP-dependent and cGMP-independent pathways
    Goldberg, JM
    Wolpin, ES
    Bosgraaf, L
    Clarkson, BK
    Van Haastert, PJM
    Smith, JL
    FEBS LETTERS, 2006, 580 (08) : 2059 - 2064
  • [2] Potent inhibition of human platelets by cGMP analogs independent of cGMP-dependent protein kinase
    Gambaryan, S
    Geiger, J
    Schwarz, UR
    Butt, E
    Begonja, A
    Obergfell, A
    Walter, U
    BLOOD, 2004, 103 (07) : 2593 - 2600
  • [3] Activation profile of cGMP-dependent protein kinase Iα
    Sabine Wolter
    Marina Golombek
    Frank Schwede
    Hans-Gottfried Genieser
    Stefan Dove
    Roland Seifert
    BMC Pharmacology and Toxicology, 14 (Suppl 1)
  • [4] The Role of cGMP-Dependent Protein Kinase in Controlling Cardiomyocyte cGMP
    Francis, Sharron H.
    CIRCULATION RESEARCH, 2010, 107 (10) : 1164 - 1166
  • [5] CGMP-DEPENDENT PROTEIN-KINASE
    LINCOLN, TM
    METHODS IN ENZYMOLOGY, 1983, 99 : 62 - 71
  • [6] Roles of cGMP/cGMP-dependent protein kinase in platelet activation
    Walter, U
    Gambaryan, S
    BLOOD, 2004, 104 (08) : 2609 - 2609
  • [7] Multiple Affinity States of cGMP-Specific Phosphodiesterase for Sildenafil Inhibition Defined by cGMP-Dependent and cGMP-Independent Mechanisms
    Rybalkina, Irina G.
    Tang, Xiao-Bo
    Rybalkin, Sergei D.
    MOLECULAR PHARMACOLOGY, 2010, 77 (04) : 670 - 677
  • [8] Suppression of kidney fibrosis by cGMP-dependent protein kinase I
    Elisabeth Schinner
    Andrea Schramm
    Frieder Kees
    Franz Hofmann
    Jens Schlossmann
    BMC Pharmacology and Toxicology, 14 (Suppl 1)
  • [9] Role of cGMP-dependent protein kinase I for kidney fibrosis
    Schinner, E.
    Hofmann, F.
    Schlossmann, J.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2012, 385 : 81 - 81
  • [10] cGMP-Dependent protein kinase I is crucial for postnatal neovascularization
    Aicher, A
    Urbich, C
    Feil, R
    Hofmann, F
    Heeschen, C
    CIRCULATION, 2003, 108 (17) : 28 - 28